Intracranial fibrosarcoma treated with adjuvant radiation and temozolomide: Report of a case and review of all published cases
Introduction: Fibrosarcoma is a rare brain tumour with 33 cases reported so far. However, there is no clear consensus about the nature of the disease and treatment as well as outcome. Methods: A MEDLINE search was carried out using MESH terms like intracranial fibrosarcoma, intraspinal fibrosarcoma,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2016-06-01
|
| Series: | Journal of the Egyptian National Cancer Institute |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1110036215000606 |
| Summary: | Introduction: Fibrosarcoma is a rare brain tumour with 33 cases reported so far. However, there is no clear consensus about the nature of the disease and treatment as well as outcome.
Methods: A MEDLINE search was carried out using MESH terms like intracranial fibrosarcoma, intraspinal fibrosarcoma, fibrosarcoma meninges and fibrosarcoma brain. A total of 22 case reports and series reporting a total of 33 cases were identified. We here also report a case treated in our institute with adjuvant radiation and concurrent and maintenance temozolomide.
Results: The age of presentation ranged from 2 months to 75 years (Median = 17 years). The gender ratio was found to be M:F of 1.75–1. Treatment modalities were described for 17 cases. Surgery was part of treatment in all cases while radiation was a part of treatment in 59% of cases (n = 10) and chemotherapy in 29% cases (n = 5). Survival data were available only for 8 cases and ranged from 1 day to 8 years (Median = 15.5 months).
Conclusion: Fibrosarcoma is a rare disease with dismal prognosis. Surgery remains the cornerstone of therapy. Radiation confers long term disease control and survival. Chemotherapy needs to be evaluated for these tumours to improve survival. |
|---|---|
| ISSN: | 1110-0362 |